Philipson B, Fagerholm P, Calel B, Grunge A, Hallnäs K, Lydahl E, Ohman L
Department of Ophthalmology, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden.
Acta Ophthalmol (Copenh). 1990 Oct;68(5):601-3. doi: 10.1111/j.1755-3768.1990.tb04796.x.
PMMA intraocular lenses have been modified by bonding a monolayer of Heparin molecules to the surface. These Heparin surface modified (HSM) IOLs were implanted in the capsular bag after extracapsular cataract extraction. Sixty-six patients were followed for 12 months in an open safety study. No unexpected reactions or severe complications occurred. Eighty-nine per cent of the patients obtained a visual acuity (VA) of 0.5 or more at the 12-month visit. When excluding cases with preoperative pathology only one case (1.5%) had less VA than 0.5. A mild postoperative iritis was seen during the first week after surgery, and in only three cases at a later visit. Cell precipitates were seen in a small number of cases. From this study and from earlier in vitro and in vivo animal studies we draw the conclusion that the Heparin surface modified IOLs are safe for implantation in human eyes.
通过将单层肝素分子结合到表面，聚甲基丙烯酸甲酯人工晶状体已得到改良。这些肝素表面改性（HSM）人工晶状体在囊外白内障摘除术后植入囊袋内。在一项开放性安全性研究中，对66例患者进行了12个月的随访。未发生意外反应或严重并发症。89%的患者在12个月随访时视力达到0.5或更好。排除术前有病变的病例后，只有1例（1.5%）视力低于0.5。术后第一周出现轻度虹膜炎，后期仅3例出现。少数病例可见细胞沉淀。从这项研究以及早期的体外和体内动物研究中，我们得出结论，肝素表面改性人工晶状体植入人眼是安全的。
